We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Sapient

Sapient is a biomarker discovery organization providing bespoke services for metabolomics, lipidomics and proteomics data generation and analysis, enabling biopharma sponsors to go beyond the genome to accelerate precision drug development.

Latest Content

Two scientists in lab coats analyzing data on a laptop during a drug discovery research project.

Sapient Launches DynamiQ™ As Its Next-Generation Data Insights Engine for Drug Discovery and Development

Sapient, has launched the next generation of its multi-omics and real-world data (RWD) human biology database, now branded as the DynamiQ™ Insights Engine.

Protein structure.

Sapient Partners With Alamar Biosciences To Extend Targeted Proteomics Services Using NULISA™ Assays for Cytokines, Chemokines and Inflammatory Mediators

Partnership complements Sapient’s mass spectrometry-based proteomics services, extends multi-omics solutions, and will enable development of NULISAseq™ assays under regulated guidance.

A 3D figure of a human made up of white blocks.

Sapient Announces Expanded, Enhanced Metabolite Identification Capabilities

Expansion of metabolite identification database accelerates insights, translation of findings for small molecule biomarker studies.

Protein.

Sapient Extends Multi-Omics Services With High Throughput Discovery Proteomics

New methods enable deep coverage of the blood and tissue proteome, expand capabilities for dynamic biomarker discovery to include metabolites, lipids, and proteins.

A female scientist holding a vial.

Sapient’s High Complexity CLIA Laboratory Receives Accreditation From the College of American Pathologists

Sapient has been awarded accreditation from the College of American Pathologists (CAP).

Futuristic representation of human genomics.

Industry Insight

Probing the Biomarker Landscape of Human Disease

To find out more about the importance of improving biomarker discovery and how next-generation mass spectrometry-based systems can help to fill the current gap in biomarker technologies, Technology Networks spoke with Dr. Mo Jain.

Speed, Scale, Specificity: How Next-Generation Mass Spectrometry is Transforming Small Molecule Biomarker Profiling content piece image

Speed, Scale, Specificity: How Next-Generation Mass Spectrometry is Transforming Small Molecule Biomarker Profiling

Speaking at Proteomics & Metabolomics 2022, Mohit Jain from Bruker, presented their talk on small molecule biomarkers in drug development.

Live from the Lab at Sapient: How timsTOF is helping to transform the speed and scale of small molecule biomarker discovery content piece image

Live from the Lab at Sapient: How timsTOF is helping to transform the speed and scale of small molecule biomarker discovery

Join Bruker's Erica Forsberg with Sapient Founder & CEO Mohit Jain, & Co-Founder and Head of Analytical R&D, Jeramie Watrous as they take you behind the scenes of Sapient’s lab.

Advertisement

Advertisement

Decoratvive background images

Never miss a story

with the Breaking Science News daily newsletter